Margrethe Sørgaard strengthens Calluna Pharma with over 25 years’ experience from different leading positions in clinical development and operation, medical affairs, and drug safety/pharmacovigilance. She took over her new position as Senior Vice President of Clinical Operations and Pharmacovigilance in April. Now, she is responsible for clinical operation activities pertaining to product safety and pharmacovigilance, ensuring appropriate safety assessment and surveillance, compliant regulatory authority reporting, the development and implementation of risk management strategies. She will also oversee CRO activities and tasks related to patients’ safety in clinical studies.

Sørgaard joins Calluna from BioInvent International AB where she was the Senior Director of Safety and PV, supporting product safety and assuring safety standards were compliant with global drug safety regulations. Prior to this, she was the VP and Head of Clinical Development at Circio Holding ASA and has previously gained experience in regulatory pre-and post-marketing processes and quality assurance, by serving as an EU Qualified Person for Pharmacovigilance (QPPV) while at Photocure ASA, and Head of Unit for Safety Assessment and GCP/PhV inspector at the Norwegian Medicines Agency (NOMA). She holds an M.Sc. in Biology (Physiology) from the University of Oslo.

Calluna Pharma was formed in 2023 following the merger of Oxitope Pharma and Arxx Therapeutics and is based in Oslo, Norway.